指南与共识骨质疏松与钙磷/甲状旁腺

成人恶性肿瘤高钙血症的治疗:内分泌学会临床实践指南

Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.
指南 / 共识 · J Clin Endocrinol Metab · 2023-01-01

内分泌学会多学科专家组针对成人恶性肿瘤高钙血症(HCM)提出8个临床问题并系统综述,采用GRADE方法形成推荐:强烈推荐使用地舒单抗(Dmab)或静脉双膦酸盐(BP);基于低确定性证据条件推荐优先选用Dmab、重度HCM初始联合降钙素与静脉BP或Dmab、难治/复发性HCM使用Dmab等。

要点

  • 成人HCM强烈推荐使用地舒单抗或静脉双膦酸盐治疗。
  • 条件推荐优先选用地舒单抗而非静脉双膦酸盐。
  • 重度HCM条件推荐初始联合降钙素与静脉双膦酸盐或地舒单抗。

核心结论

  • 专家组基于现有证据形成成人HCM治疗推荐,强调治疗原发恶性肿瘤对控制高钙血症及预防复发至关重要。

研究设计与样本

  • 多学科临床专家组联合系统综述专家确定8个成人HCM治疗相关临床问题,系统综述检索电子数据库,采用GRADE方法评估证据确定性并形成推荐,并行独立系统综述评估患者与医生价值观偏好、成本、资源、可接受性、可行性、公平性等证据到决策框架相关领域。

主要发现

  • 专家组强烈推荐成人HCM使用地舒单抗或静脉双膦酸盐治疗。
  • 基于低确定性证据,条件推荐成人HCM使用地舒单抗而非静脉双膦酸盐。
  • 基于低确定性证据,条件推荐重度HCM初始治疗联合降钙素与静脉双膦酸盐或地舒单抗。
  • 基于低确定性证据,条件推荐难治/复发性HCM(尽管已使用双膦酸盐)使用地舒单抗。
  • 基于低确定性证据,条件推荐对高骨化三醇相关肿瘤所致高钙血症且已接受糖皮质激素治疗但仍存在重度或症状性HCM的成人患者,加用静脉双膦酸盐或地舒单抗;对甲状旁腺癌所致高钙血症成人患者,条件推荐使用拟钙剂或抗骨吸收治疗(静脉双膦酸盐或地舒单抗)。

关键数值与推荐

  • 成人HCM:强烈推荐地舒单抗或静脉双膦酸盐治疗。
  • 成人HCM:条件推荐地舒单抗而非静脉双膦酸盐(低确定性证据)。
  • 重度HCM:条件推荐初始联合降钙素与静脉双膦酸盐或地舒单抗(低确定性证据)。
  • 难治/复发性HCM(尽管使用双膦酸盐):条件推荐地舒单抗(低确定性证据)。
  • 高骨化三醇相关肿瘤所致高钙血症且已用糖皮质激素但仍重度或症状性HCM:条件推荐加用静脉双膦酸盐或地舒单抗;甲状旁腺癌所致高钙血症:条件推荐拟钙剂或抗骨吸收治疗(静脉双膦酸盐或地舒单抗)(低确定性证据)。

临床怎么用

  • 专家组判断多数推荐的治疗可能可及且可行,但注意到成本、所需资源及其对公平性的影响存在差异。
  • 治疗原发恶性肿瘤对控制高钙血症和预防复发具有关键作用。

局限性

  • 推荐基于低确定性证据。
  • 专家组注意到成本、所需资源及其对公平性的影响存在差异。
  • 指南强调当前知识空白可用于建立未来研究议程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypercalcemia of malignancy (HCM) is the most common metabolic complication of malignancies, but its incidence may be declining due to potent chemotherapeutic agents. The high mortality associated with HCM has declined markedly due to the introduction of increasingly effective chemotherapeutic drugs. Despite the widespread availability of efficacious medications to treat HCM, evidence-based recommendations to manage this debilitating condition are lacking. OBJECTIVE: To develop guidelines for the treatment of adults with HCM. METHODS: A multidisciplinary panel of clinical experts, together with experts in systematic literature review, identified and prioritized 8 clinical questions related to the treatment of HCM in adult patients. The systematic reviews (SRs) queried electronic databases for studies relevant to the selected questions. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make recommendations. An independent SR was conducted in parallel to assess patients' and physicians' values and preferences, costs, resources needed, acceptability, feasibility, equity, and other domains relevant to the Evidence-to-Decision framework as well as to enable judgements and recommendations. RESULTS: The panel recommends (strong recommendation) in adults with HCM treatment with denosumab (Dmab) or an intravenous (IV) bisphosphonate (BP). The following recommendations were based on low certainty of the evidence. The panel suggests (conditional recommendation) (1) in adults with HCM, the use of Dmab rather than an IV BP; (2) in adults with severe HCM, a combination of calcitonin and an IV BP or Dmab therapy as initial treatment; and (3) in adults with refractory/recurrent HCM despite treatment with BP, the use of Dmab. The panel suggests (conditional recommendation) the addition of an IV BP or Dmab in adult patients with hypercalcemia due to tumors associated with high calcitriol levels who are already receiving glucocorticoid therapy but continue to have severe or symptomatic HCM. The panel suggests (conditional recommendation) in adult patients with hypercalcemia due to parathyroid carcinoma, treatment with either a calcimimetic or an antiresorptive (IV BP or Dmab). The panel judges the treatments as probably accessible and feasible for most recommendations but noted variability in costs, resources required, and their impact on equity. CONCLUSIONS: The panel's recommendations are based on currently available evidence considering the most important outcomes in HCM to patients and key stakeholders. Treatment of the primary malignancy is instrumental for controlling hypercalcemia and preventing its recurrence. The recommendations provide a framework for the medical management of adults with HCM and incorporate important decisional and contextual factors. The guidelines underscore current knowledge gaps that can be used to establish future research agendas.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. El-Hajj Fuleihan G, Clines GA, Hu MI, et al. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2023. PMID: 36545746. doi:10.1210/clinem/dgac621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。